Aratana Therapeutics (PETX) Tops Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AAPL
2. AMD
3. PLTR
4. DOX
5. VRTX
6. CHKP
7. CRWD
8. ON
9. INSP
10. CVI

Go back to Aratana Therapeutics (PETX) Tops Q2 EPS by 1c

Aratana Therapeutics Reports Second Quarter 2017 Financial Results

August 3, 2017 4:30 PM EDT

LEAWOOD, Kan., Aug. 3, 2017 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced its second quarter 2017 financial results. For the quarter ended June 30, 2017, Aratana reported total net revenues of $5.2 million and a net loss of $10.4 million or $0.26 diluted loss per share.

"We are pleased with the continued customer adoption of Galliprant and Nocita," stated Steven St. Peter, M.D., President and Chief... More